Puma Biotechnology Presents Updated Findings from the TBCRC-

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster (PD7-03), entitled “Nerat...

Related Keywords

United States , San Antonio , Texas , Rachela Freedman , Alanh Auerbach , European Commission , Drug Administration , Susanf Smith Center , Nasdaq , Exchange Commission , Puma Biotechnology Inc , Translational Breast Cancer Research Consortium , Dana Farber Cancer Institute , Breast Oncology Center , Puma Biotechnology , Antonio Breast Cancer Symposium , Breast Cancer Brain Metastases , Spotlight Poster Session , Response Assessment , Neuro Oncology Brain Metastases , Response Rate , Dana Farber Cancer , Puma Patient Lynx , Fetal Toxicity , Full Prescribing Information , Annual Report ,